Literature DB >> 2410121

Clinical pharmacokinetics of vindesine infusion.

R Rahmani, J P Kleisbauer, J P Cano, M Martin, J Barbet.   

Abstract

Fifteen patients were given vindesine (VDS) either by iv bolus injections at doses ranging from 0.7 to 1.2 mg/m2 or by 5-day infusions (total dose: 5 mg/m2), in combination with cisplatin (20 mg/m2/day) and bleomycin (6 mg/m2/day) for 5 days. For bolus injections, the total dose of VDS in one treatment was completed to 5 mg/m2 by infusion on Days 4 and 5. Drug concentrations in plasma and urine were measured by radioimmunoassay. Plasma concentration decay curves after bolus injection presented the expected triphasic shape, whereas for infusions, plasma concentrations increased and reached steady-state after about 30 hours and declined in a biphasic way after infusion discontinuation. Steady-state concentrations ranged from 4 to 15 micrograms/L and showed important variations among patients. Clearances estimated from the area under the concentration-time curves were significantly smaller for infusions than for bolus injections. This observation was interpreted as an indication of VDS pharmacokinetic nonlinearity. Terminal half-lives and renal clearances were not significantly different for the two types of administration. Toxicity of the treatment was generally limited, except for one major renal failure; two patients showed objective tumor regression after therapy.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2410121

Source DB:  PubMed          Journal:  Cancer Treat Rep        ISSN: 0361-5960


  6 in total

1.  P-glycoprotein inhibition leads to enhanced disruptive effects by anti-microtubule cytostatics at the in vitro blood-brain barrier.

Authors:  I C van der Sandt; P J Gaillard; H H Voorwinden; A G de Boer; D D Breimer
Journal:  Pharm Res       Date:  2001-05       Impact factor: 4.200

2.  In vivo and in vitro pharmacokinetics and metabolism of vincaalkaloids in rat. II. Vinblastine and vincristine.

Authors:  X J Zhou; M Martin; M Placidi; J P Cano; R Rahmani
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1990 Oct-Dec       Impact factor: 2.441

3.  In vivo and in vitro pharmacokinetics and metabolism of vincaalkaloids in rat. I. Vindesine (4-deacetyl-vinblastine 3-carboxyamide).

Authors:  R Rahmani; X J Zhou; M Placidi; M Martin; J P Cano
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1990 Jan-Mar       Impact factor: 2.441

Review 4.  Preclinical and clinical pharmacology of vinca alkaloids.

Authors:  X J Zhou; R Rahmani
Journal:  Drugs       Date:  1992       Impact factor: 9.546

5.  Pharmacokinetics of navelbine after oral administration in cancer patients.

Authors:  X J Zhou; P Boré; S Monjanel; Z Sahnoun; R Favre; A Durand; R Rahmani
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

6.  Phase I study of 21 days continuous infusion with vindesine.

Authors:  E G de Vries; E F Smit; D E Vendrig; J J Holthuis; N H Mulder
Journal:  Br J Cancer       Date:  1989-03       Impact factor: 7.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.